These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 33789642)

  • 1. Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial.
    Watson DP; Swartz JA; Robison-Taylor L; Mackesy-Amiti ME; Erwin K; Gastala N; Jimenez AD; Staton MD; Messmer S
    BMC Public Health; 2021 Mar; 21(1):630. PubMed ID: 33789642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.
    Gustafson DH; Landucci G; McTavish F; Kornfield R; Johnson RA; Mares ML; Westergaard RP; Quanbeck A; Alagoz E; Pe-Romashko K; Thomas C; Shah D
    Trials; 2016 Dec; 17(1):592. PubMed ID: 27955689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.
    Corneli A; Perry B; Des Marais A; Choi Y; Chen H; Lilly R; Ayers D; Bennett J; Kestner L; Meade CS; Sachdeva N; McKellar MS
    Harm Reduct J; 2022 Dec; 19(1):132. PubMed ID: 36463214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of a medical student-run telemedicine program for medications for opioid use disorder during the COVID-19 pandemic.
    Castillo M; Conte B; Hinkes S; Mathew M; Na CJ; Norindr A; Serota DP; Forrest DW; Deshpande AR; Bartholomew TS; Tookes HE
    Harm Reduct J; 2020 Nov; 17(1):88. PubMed ID: 33203460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Bundling Medication for Opioid Use Disorder With an mHealth Intervention Targeting Addiction: A Randomized Clinical Trial.
    Gustafson DH; Landucci G; Vjorn OJ; Gicquelais RE; Goldberg SB; Johnston DC; Curtin JJ; Bailey GL; Shah DV; Pe-Romashko K; Gustafson DH
    Am J Psychiatry; 2024 Feb; 181(2):115-124. PubMed ID: 37789744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of Telemedicine Delivery of Medications for Opioid Use Disorder in Pennsylvania Treatment Programs During COVID-19.
    Poulsen MN; Santoro W; Scotti R; Henderson C; Ruddy M; Colistra A
    J Addict Med; 2023 Mar-Apr 01; 17(2):e110-e118. PubMed ID: 36129690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.
    Bartholomew TS; Plesons M; Serota DP; Alonso E; Metsch LR; Feaster DJ; Ucha J; Suarez E; Forrest DW; Chueng TA; Ciraldo K; Brooks J; Smith JD; Barocas JA; Tookes HE
    Addict Sci Clin Pract; 2024 Mar; 19(1):21. PubMed ID: 38528570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
    J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder.
    Ober AJ; Murray-Krezan C; Page K; Friedmann PD; Chan Osilla K; Ryzewicz S; Huerta S; Mazer MW; Leamon I; Messineo G; Watkins KE; Nuckols T; Danovitch I
    Addict Sci Clin Pract; 2022 Jul; 17(1):39. PubMed ID: 35902888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study.
    Livingston NA; Sarpong A; Sistad R; Roth C; Banducci AN; Simpson T; Hyde J; Davenport M; Weisberg R
    J Subst Use Addict Treat; 2024 Jan; 156():209188. PubMed ID: 37866437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorder.
    Bart G; Korthuis PT; Donohue JM; Hagedorn HJ; Gustafson DH; Bazzi AR; Enns E; McNeely J; Ghitza UE; Magane KM; Baukol P; Vena A; Harris J; Voronca D; Saitz R
    Addict Sci Clin Pract; 2024 Apr; 19(1):29. PubMed ID: 38600571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.
    Jakubowski A; Fowler S; Fox AD
    Addict Sci Clin Pract; 2023 Jun; 18(1):40. PubMed ID: 37301953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree.
    Ijioma SC; Pontinha VM; Holdford DA; Carroll NV
    J Manag Care Spec Pharm; 2021 Feb; 27(2):137-146. PubMed ID: 33506729
    [No Abstract]   [Full Text] [Related]  

  • 18. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
    Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
    J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
    Chan B; Bougatsos C; Priest KC; McCarty D; Grusing S; Chou R
    Subst Abus; 2022; 43(1):539-546. PubMed ID: 34520702
    [No Abstract]   [Full Text] [Related]  

  • 20. Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial.
    Thompson RG; Bollinger M; Mancino MJ; Hasin D; Han X; Bush KA; Kilts CD; James GA
    Trials; 2023 Apr; 24(1):255. PubMed ID: 37016394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.